Wiederkehr Julio Cesar, Avilla Sylvio Gilberto, Mattos Elisângela, Coelho Izabel Meister, Ledesma Jorge Alberto, Conceição Alexandra Fernandes, Wiederkehr Henrique Aguiar, Wiederkehr Barbara Aguiar
Federal University of Paraná, Curitiba Brazil; Division of Liver Transplantation and Surgery, Hospital Pequeno Príncipe, Curitiba Brazil.
Division of Liver Transplantation and Surgery, Hospital Pequeno Príncipe, Curitiba Brazil.
J Pediatr Surg. 2015 Jul;50(7):1227-31. doi: 10.1016/j.jpedsurg.2014.10.019.
Resection is the only curative treatment option for primary and secondary malignant tumors of the liver. Although curative resection is associated with long-term survival rates, it can only be performed in 10% of patients with primary tumors and 25% of patients with liver metastases. Liver insufficiency is one of the most serious postoperative complications of patients undergoing extensive liver resections. When total liver resection is necessary liver transplant is mandatory, with the burden of long-term immunosuppression and its complications. Among several different strategies to increase the resectability of liver tumors, portal vein occlusion (embolization or ligature), bilateral tumor resection in two stages, and resection combined with loco regional therapy are the most popular. A new strategy for patients with marginally resectable liver tumors previously considered to be unresectable was formally reported by Baumgart et al. in 2011, originally developed by Hans Schlitt in 2007. This technique consists of a two-staged hepatectomy with initial portal vein ligation and in situ splitting of the liver parenchyma, and it is known as ALPPS (associating liver partition with portal vein ligation for staged hepatectomy). The aim of this study is to present the first series of pediatric patients with marginally resectable liver tumors previously considered to be unresectable treated with two-stage hepatectomy with initial portal vein ligation and in situ splitting of the liver parenchyma. Two patients were diagnosed with hepatoblastoma, and one each with rhabdomyosarcoma, hepatocellular carcinoma, and nodular focal hyperplasia. ALPPS technique was considered whenever the future liver remnant (FLR) was 40% or less of the total liver volume (TLV) determined by CT or MRI scans. The ratio of FLR to TLV before the first procedure ranged from 0.15 to 0.38, with a mean±sd of 0.253±0.07. In all patients, a rapid growth of the FLR was observed. Estimates of the FRL volume prior to surgical treatment ranged from 110cc to 750cc, with a mean±sd of 361.6±213.75cc. Just before the second procedure, the volume of the remnant liver ranged from 225cc to 910cc, with a mean±sd of 563.6cc±221.7cc. The FRL volume increase had a mean±sd of 72.56%±29.05%, with a median of 83.8%. The second procedure was performed after 7 to 12days with a median of 11days. The only postoperative complication observed in one patient was an asymptomatic right pleural effusion that was aspirated during the second procedure with no further complications. ALPPS was shown to be effective and a safe procedure to treat large tumors in children.
肝切除术是治疗原发性和继发性肝脏恶性肿瘤的唯一根治性治疗选择。尽管根治性肝切除术与长期生存率相关,但仅10%的原发性肿瘤患者和25%的肝转移患者能够进行该手术。肝衰竭是接受广泛肝切除术患者最严重的术后并发症之一。当需要进行全肝切除时,肝移植是必需的,但会带来长期免疫抑制及其并发症的负担。在几种不同的提高肝肿瘤可切除性的策略中,门静脉阻断(栓塞或结扎)、两阶段双侧肿瘤切除以及联合局部区域治疗是最常用的。Baumgart等人于2011年正式报道了一种针对先前被认为不可切除的边缘可切除性肝肿瘤患者的新策略,该策略最初由Hans Schlitt于2007年开发。该技术包括两阶段肝切除术,初始门静脉结扎和肝实质原位劈离,被称为ALPPS(联合肝脏分隔与门静脉结扎分期肝切除术)。本研究的目的是展示首例采用初始门静脉结扎和肝实质原位劈离的两阶段肝切除术治疗先前被认为不可切除的边缘可切除性肝肿瘤的儿科患者系列。两名患者被诊断为肝母细胞瘤,另外各有一名患者被诊断为横纹肌肉瘤、肝细胞癌和结节性局灶性增生。只要未来肝脏残余体积(FLR)经CT或MRI扫描确定为全肝体积(TLV)的40%或更低,就考虑采用ALPPS技术。第一次手术前FLR与TLV的比值范围为0.15至0.38,平均值±标准差为0.253±0.07。所有患者均观察到FLR快速增长。手术治疗前FRL体积估计范围为110cc至750cc,平均值±标准差为361.6±213.75cc。就在第二次手术前,残余肝脏体积范围为225cc至910cc,平均值±标准差为563.6cc±221.7cc。FRL体积增加的平均值±标准差为72.56%±29.05%,中位数为83.8%。第二次手术在7至12天(中位数为11天)后进行。仅一名患者观察到术后并发症,为无症状性右侧胸腔积液,在第二次手术时进行了抽吸,未出现进一步并发症。ALPPS被证明是治疗儿童大肿瘤的有效且安全的手术。